Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07103408CT.gov A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06719700CT.gov Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05595889CT.gov Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05668767CT.gov Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC | — | Unknown | — | — | — |
NCT05509699CT.gov Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04996771CT.gov Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04579757CT.gov Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Surufatinib (this asset) | Sun Yat-sen University | P2 | CCC · 55 |
| Benmelstobart | Yayi He | P4 | A |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| hs-20093 | Shanghai Hansoh Biomedical Co., Ltd | P3 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Surufatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuroendocrine Neoplasm | — | P3 | BB · 64 |
| Malignant Pancreatic Neoplasm | — | P3 | BB · 64 |
| Colorectal Cancer | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Surufatinib in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/surufatinib-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →